

## MEDICARE ADVANTAGE PRIOR AUTHORIZATION REQUEST FORM

Taltz - Medicare

Phone: 215-991-4300 Fax back to: 866-371-3239

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.		
Member Name:	Prescriber Name:	
Member Number:	Fax: Phone:	
Date of Birth:	Office Contact:	
Line of Business:   Medicare Advantage	NPI: State Lic ID:	
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	
REQUEST FOR EXPEDITED REVIEW: By checking this box and signing below, he life or health of the enrollee or the enrollee's ability to regain maximum functions.	I certify that applying the 72 hour standard review timeframe may seriously jeopardize tion.	
Drug Name:		
Strength:		
Directions / SIG:		
Please attach any pertinent medical history including labs and information for this member that may support approval.  Please answer the following questions and sign.		
Q1. Is this a reauthorization request? If YES, go to 2. If NO, go to 3.		
☐ Yes	□ No	
Q2. Is there confirmation of continued positive clinical response since starting Taltz?		
☐ Yes	□ No	
Q3. Is the medication prescribed by or in consultation with a dermatologist or rheumatologist?		
☐ Yes	□ No	
Q4. Is there a confirmation of tuberculosis (TB) screening results and treatment plan for active or latent infection?		
☐ Yes	□ No	
Q5. Does the patient have a confirmed diagnosis of moderate to severe plaque psoriasis (PsO)?		
☐ Yes	□ No	



## MEDICARE ADVANTAGE PRIOR AUTHORIZATION REQUEST FORM

Taltz - Medicare

Phone: 215-991-4300 Fax back to: 866-371-3239

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Member Name:	Prescriber Name:	
Q6. Is the patient 6 to 17 years of age?		
□Yes	□ No	
Q7. Is there documentation of an inadequate response, intolerance, or contraindication to Enbrel?		
☐ Yes	□ No	
Q8. Is the patient 18 years of age or older?		
□Yes	□No	
Q9. Is there documentation of an inadequate response, intolerance, or contraindication to: Enbrel, Humira, Otezla, or Skyrizi?		
☐ Yes	□No	
Q10. Does the patient have a confirmed diagnosis of active psoriatic arthritis (PsA)?		
□Yes	□No	
Q11. Is the patient 18 years of age or older?		
□Yes	□No	
Q12. Is there documentation of inadequate response, intolerance, or contraindication to Enbrel, Humira, Otezla, Rinvoq, Skyrizi, OR Xeljanz/Xeljanz XR?		
☐ Yes	□ No	
Q13. Does the patient have a confirmed diagnosis of active ankylosing spondylitis (AS)?		
☐ Yes	□No	
Q14. Is the patient 18 years of age or older?		
☐ Yes	□No	



## MEDICARE ADVANTAGE PRIOR AUTHORIZATION REQUEST FORM

Taltz - Medicare

Phone: 215-991-4300 Fax back to: 866-371-3239

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Member Name:	Prescriber Name:	
Q15. Is there documentation of inadequate response, intolerance, or contraindication to Enbrel, Humira, Rinvoq, or Xeljanz/Xeljanz XR?		
☐ Yes	□ No	
Q16. Does the patient have a confirmed diagnosis of non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation?		
☐ Yes	□ No	
Q17. Is the patient 18 years of age or older?		
☐ Yes	□ No	
Q18. Is there documentation of inadequate response, intolerance, or contraindication to Rinvoq?		
☐ Yes	□ No	
Q19. Requested Duration:		
☐ 12 Months	☐ Other:	
Q20. Additional Information:		
Prescriber Signature	Date	

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document

v2025